Celcuity

Celcuity
Pharma

Celcuity set to be Big Pharma 'strategic target' after approval

The biotech's Revtorpyk, also in development for prostate cancer and other solid tumors, has the potential to generate multibillion-dollar sales.
Darren Incorvaia Jul 14, 2026 4:56pm